Eculizumab biosimilar gets positive CHMP opinion
Samsung Bioepis’ first haematology biosimilar, which references Soliris (eculizumab), has been recommended for approval by the CHMP.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
